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The association between fluid intake and bladder cancer risk remains controversial. Very little is known about to which extent the
amount of water intake influences the action of excreting toxics upon the urinary system. This proof of concept trial investigates
the effect of water intake on mutagenesis in smokers, a high risk population for bladder cancer.Methods. Monocentric randomized
controlled trial. Inclusion Criteria. Male subjects aged 20–45 y/o, smokers, and small drinkers (24-hour urinary volume <1 L and
osmolality >700mOsmol/kg). Outcomes. 4-ABP DNA adducts formation in exfoliated bladder cells in 24-hour urine collection
and urinary mutagenicity in 24-hour urine. Test Group. Subjects consumed 1.5 L daily of the study product (EVIAN) on top of their
usual water intake for 50 days. Control Group. Subjects continued their usual lifestyle habits. Results. 65 subjects were randomized.
Mean age was 30 y/o and mean cigarettes per day were 20. A slight decrease in adducts formation was observed between baseline
and last visit but no statistically significant difference was demonstrated between the groups. Urinary mutagenicity significantly
decreased. The study shows that increasing water intake decreases urinary mutagenicity. It is not confirmed by urinary adducts
formation. Further research would be necessary.
1. Introduction
Tobacco smoking andoccupational exposure to chemicals are
leading causes of urinary bladder cancer [1].This is thought to
be largely due to exposure to aromatic amines, which, when
activated, can react withDNA to formDNA adducts thatmay
induce mutations in key cancer-related genes [1]. Metabolites
of aromatic amines are mainly excreted in the urine [2–
4], and bladder biopsies and exfoliated urothelial cells from
exposed populations contain increased levels ofDNAadducts
specifically associated with bladder cancer, benzidine and 4-
aminobiphenyl (4-ABP) [5, 6]. Since smokers and workers
exposed to polycyclic aromatic hydrocarbons (PAH) also
excrete increased amounts of mutagens into their urine, it
is possible that PAH also contribute to the increased risk of
urinary bladder cancer. Indeed, we have recently reported
that PAH exposure in coke oven workers is associated with
increased levels of DNA adducts that are correlated with
levels of urinary 1-hydroxypyrene in the absence of aromatic
amine exposure [7]. The mutagenic profile of smokers urine
suggests that both aromatic amines and PAH materials are
excreted at increased levels. Increasing fluid intake could
potentially reduce the impact of urinary bladder carcinogen
exposure, either through simple dilution and/or by decreas-
ing the time the carcinogen spends in the urinary bladder
because of increasedmicturition frequency. In either case one
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might expect that an increase in water intake would induce
lower levels of urinarymutagens, DNAadducts in the urinary
bladder, and, perhaps, the risk of urinary bladder cancer.
Results from epidemiological studies investigating the
association between fluid intake and bladder cancer have
been inconsistent. Recently, Ros et al. reported no association
between total fluid intake and bladder cancer using data
from the European Prospective Investigation into Cancer
and Nutrition cohort study [8]. On the other hand, in two
large case-control studies, Michaud et al. found an inverse
association between total fluid and plain water intake and
the risk of bladder cancer, although no such relationship was
found for other beverages [9, 10]. Jiang et al. also reported an
association between dailywater intake and a slight decrease in
bladder cancer risk as well as an inverse relationship between
urination frequency and bladder cancer risk for subjects who
urinated at least six times per day [11]. Furthermore, the risk
of bladder cancer is inversely related to nighttime voiding fre-
quency [12], and urination frequency appears to be one of the
four main factors contributing to interindividual differences
in DNA binding by 4-ABP in human bladder [13]. Finally,
experiments in dogs indicate that exposure to N-hydroxy-4-
ABP and 4-ABP-DNA adduct formation in the bladder are
inversely correlated with urination frequency [14].
Consequently, further investigation of the ability of
increased water intake to reduce the risk of bladder can-
cer and exposure to aromatic amines is warranted. Our
hypothesis was that increasing water intake will reduce the
exposure of urothelial cells to mutagens in the urine. First,
increasing water intake leads to an increased urine output.
This means that urine is diluted, that is, less concentrated
in toxic substances. Second, increased urination frequency
decreases the duration of urothelial cell exposure to toxic sub-
stances.Thus, increasedwater intake should lead to decreased
exposure concentration for less time and reduce the contact
time of the mutagens with the target cells. To the best of
our knowledge, this hypothesis has not been investigated in
humans previously. Here, we report the results of a proof-
of-concept, randomized, controlled study on the effects of
increased bottled water intake on urinary DNA adduct levels
and mutagenicity in moderate to heavy smokers.
2. Materials and Methods
2.1. Study Design. This was a single-center, randomized,
controlled, open-label, two-parallel group study in healthy
male low water consumers who smoke (ClinicalTrials.gov
no. NCT01583387). The study was conducted at Centre CAP
(Montpellier, France) between February 21 and July 4, 2011.
Theprimary objectives of this studywere to assess the effect of
increased water intake on the mutagenicity of smokers’ urine
and subsequent formation of 4-ABP andBPDE-DNAadducts
in exfoliated bladder cells in 24-hour urine.
2.2. Ethics. The study was approved by the independent
ethics committee of Sud Mediterrane´e III, France, and the
Agence Nationale de Se´curite´ duMe´dicament et des Produits
de Sante´, France, and it was carried out in accordance with
the Declaration of Helsinki and the International Conference
on Harmonization Guidelines for Good Clinical Practice. All
subjects gave their written informed consent before inclusion
in the study.
2.3. Subjects. Male smokers 20 to 45 years of age were
recruited for this study. Potential subjects were screened
about their smoking habits by telephone. To be included
in the study, they had to have a moderate or high level of
dependence on cigarette smoking as indicated by a score ≥5
on the Fagerstro¨m Test for Nicotine Dependence [15] and
had to smoke ≥15 cigarettes/day for the last 2 years. Those
eligible had an initial visit with the study investigator, where
they were given a diary in which they recorded dietary and
smoking habits for 2 weeks. To be included and randomized,
subjects had to drink ≤1 L of fluid and ≤500mLwater per day,
have a urine osmolality >700mOsmol/kg, have a body mass
index of 18–27 kg/m2, had to eat 3 meals per day, and had to
be covered by the French national health insurance system.
Subjects were excluded if they had a history of metabolic
disease or acute or chronic gastrointestinal disease except
appendectomy; were diagnosed with urinary tract, lung, or
respiratory disease; regularly consumed more than three
units (12 g) of alcohol per day; or were taking or addicted
to drugs (e.g., cannabis, opioids, or amphetamines). Subjects
were also excluded if they handled paints, dry cleaning chem-
icals, dyes, pesticides, aluminum, or asphalt; ate grilled foods
more than three times per week; were vegetarian; participated
in intense physical activity; could not or were not willing to
increase their fluid intake by 1.5 L per day; were planning to
stop or reduce their smoking or change brand of cigarettes
during the study; or had evidence or a history of disease, were
receiving treatment, or had any other situation that, in the
investigator’s opinion, could affect the study parameters.
2.4. Study Conduct. Eligible subjects were randomized 1 : 1
to the test or control group. The randomization list was
generated using SAS version 9.2 (SAS Institute, Cary, NC),
and subjects were assigned to groups sequentially. Subjects
assigned to the test group had to consume three 500mL
bottles daily of natural mineral water (Evian, Danone, Paris,
France) in addition to their usual water intake for 50 consecu-
tive days. Bottles were opened at the beginning of every meal
(breakfast, lunch, and dinner) and had to be fully consumed
before the next meal. Subjects in the control group continued
their normal fluid consumption.
At screening, investigators recorded physical characteris-
tics, demographics, smoking behavior, alcohol consumption
behavior, medical history, and concomitant medication. In
addition, smoking habits were assessed at randomization and
study end using the Fagerstro¨m Test for Nicotine Depen-
dence [15].
At baseline and at the end of the study, subjects were
asked to collect 24-hour urine. They were trained by the
study nurses to obtain a complete collection and to store
the samples under appropriate conditions (approximately
4∘C). The first urine on day 1 was excluded. If one urination
was missing, the subject was asked to make a new 24-hour
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urine collection. Blood samples (18mL) were collected from
subjects. Subjects were asked to complete an online food and
fluid questionnaire for 3 days before both visits. Information
in online diaries includedmeal type (breakfast, lunch, dinner,
or snack), time, location, composition, and quantity of each
component; type of fluid intake and time and quantity of each
consumption; andnumber of urinations per day. Subjects also
completed the fluid intake diary once per week during the
intervention period. Finally, the test group was also provided
with a printed diary in which they recorded their daily con-
sumption of each bottle of water administered for the study.
2.5. Urine Analysis. The 24-hour urine was collected in a
specific (sterile container of 2.7 L with screw cap, without
preservative) container during 24 h and stored at about +4∘C
to ensure the stability of analysed parameters. Then for DNA
adduct analysis, a volume of a 50% glycerol solution was
added to the containers (one volume of glycerol solution was
added to four volumes of urine) to reduce cell lysis during
the freezing-thawing of the samples. Urinary mutagenicity
was assessed with the Salmonella-microsome assay using
the strain Salmonella typhimurium YG1041 in the presence
of the metabolic fraction S9 Mix [16]. Exfoliated bladder
cells were isolated and 4-ABP-DNA and BPDE-DNA adducts
in exfoliated bladder cells were measured as previously
described [16, 17]. The values for each individual were the
mean of at least two independent replicate samples. For each
DNA adduct, results are expressed as the number of adducts
per 108 unadducted nucleotides. Total volume of urine was
calculated as urine weight (g) ÷ urine specific gravity (g/L).
2.6. Safety. At each visit, subjects were asked if they had
experienced any adverse events (AE) since the last visit.
AEs were defined as any unwanted effect whether or not
related to the study product. Abnormal laboratory results
were not considered AEs except when indicative of disease
or organ toxicity. For each AE, investigators recorded the
severity (mild, moderate, and severe), relationship to the
study product (unrelated or unlikely, possibly, probably, or
definitely related), and treatments for each event. Severe
adverse events were defined as any AE that resulted in
death; was life-threatening; resulted in disability, permanent
incapacity, hospitalization, or prolonged hospitalization; or
was medically important in the investigator’s opinion.
2.7. Determination of Sample Size. Due to a lack of infor-
mation on clinically relevant effects, the sample size was
arbitrarily set at 30 subjects per group. This sample size
was estimated to provide 35% precision for determination of
the primary outcome measure (4-ABP-DNA level) and the
minimum needed to perform analysis of variance (ANOVA).
Considering an estimated 10% dropout of enrolled subjects, a
total of 66 subjects were planned.
2.8. Statistical Analysis. Statistical analysis was performed
using SAS version 9.2. Safety, demographics, and baseline
characteristics were assessed in the full analysis set, which
included all subjects randomized. Primary and secondary
endpoints were assessed in all subjects completing the study
according to protocol as well as in all subjects randomized
and for whom data were available. For continuous outcomes,
the main model was a generalized linear model on the raw
change of the value with the study group as fixed factor,
value at baseline, and number of cigarettes consumption
at baseline as covariate. All adduct measures were log-
transformed to provide normally distributed data. Before
being log-transformed, themeasures equal to 0 were replaced
by 0.1 (limit of detection divided by two). The underlying
assumptions of normality of residuals for analysis of variance
model were checked by using skewness and kurtosis statistics.
A distribution was considered as approximately normal if the
values of skewness and kurtosis fell within the interval of
−1.5 to 1.5. In case of nonnormality, a nonparametric analysis
(Wilcoxon test) was performed. Differences were considered
statistically significant at 𝑝 < 0.05.
3. Results
3.1. Safety. No treatment-related adverse events were report-
ed, and no clinically significant abnormalities and no serious
adverse events were reported. Biological parameters, urinaly-
sis dipstick results, and vital signs remained stable during the
study (data not shown).
3.2. Demographics and Baseline Characteristics. A total of 118
male smokers were contacted and 110 were enrolled. Of these,
65 were eligible for randomization after the 2-week screening
period. Of these, 33 were randomized into the test group and
32 into the control group. In both groups, the subjects were 20
to 45 years of age and baseline characteristics and tobacco and
drinking habits were similar (Table 1). All subjects smoked
blond tobacco, most smoked exclusively cigarettes, and most
smoked filtered cigarettes.
Two subjects from the test group and one subject from
the control group voluntarily withdrew from the study before
its completion on day 50. Thus, 31 subjects in each group
completed the study.
3.3. Fluid Intake and Water Intake Compliance. According to
data collected from online diaries, total fluid intake at base-
line was 600.8±173.8mL for the test group and 602.3±165.2
for the control group. Total fluid intake increased on average
(adjusted mean ± standard error) to 2127.2 ± 243.5mL in
the test group but changed little (602.0 ± 153.1mL) in the
control group.Meanwater intake (± standard deviation (SD))
in the test group increased from 247.2 ± 104.1mL at baseline
to 1612.3±131.6mL at study end.Water intake in the control
group remained relatively stable, starting at 229.1 ± 98.9mL
at baseline and finishing at 257.5 ± 100.0mL at study end.
Subjects in the test group consumed between 98% and 108%
(median, 100%) of the additional 1.5 L of water that they were
instructed to drink.
In the test group, the urine volume increased from
0.789 ± 0.164 L to 2.112 ± 0.607 L at the end of the study.
Accordingly, the number of urinations per day increased
from 3.7 ± 1.6 to 6.7 ± 2.3. By contrast, in the control
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Table 1: Subject demographics and baseline characteristics.




Mean ± SD 28.5 ± 7.4 30.6 ± 6.8
Range 20–45 20–45
Weight (kg)




Mean ± SD 22.46 ± 3.03 23.51 ± 2.25
Range 18.1–27.0 18.6–26.9
Type of tobacco
Blond 32 (100%) 32 (100%)
Filter use
Yes 30 (93.8%) 28 (87.5%)
No 2 (6.3%) 4 (12.5%)
Tar/cigarette
<3mg 0 (0.0%) 0 (0.0%)
3–6mg 1 (3.1%) 1 (3.1%)
7–10mg 26 (81.3%) 29 (90.6%)
>10mg 2 (6.3%) 0 (0.0%)
Unknown 3 (9.4%) 2 (6.3%)
Smoking in addition to
cigarettes
None 31 (96.9%) 28 (87.5%)
Cigarillos 0 (0.0%) 1 (3.1%)
Water pipes 1 (3.1%) 2 (6.3%)
Other 0 (0.0%) 1 (3.1%)
Cigarette smoking/day
by others in the
household
None 22 (68.8%) 16 (50.0%)
≤10 6 (27.3%) 2 (12.5%)
11–20 8 (36.4%) 9 (56.3%)
21–30 2 (9.1%) 4 (25.0%)
>30 6 (27.3%) 1 (6.3%)
Fagerstro¨m score
Mean ± SD 6.9 ± 1.4 7.0 ± 1.3
Range 5–10 5–9
Cigarettes smoked/day
Mean ± SD 19.9 ± 6.2 20.8 ± 6.1
Range 15–40 15–40
Duration of smoking (y)




<2 26 (81.3%) 27 (84.4%)
2 or 3 6 (18.8%) 5 (15.6%)
>3 0 (0.0%) 0 (0.0%)
Values are shown for all subjects randomized and for whom data were
available. Note that no data were available for one subject randomized to the
test group. SD, standard deviation.
group, the change in urine volume from baseline was −0.04±
0.07 L and in the number of urinations/day was −0.2 ±
0.9. Blood osmolality, which reflects intracellular osmolality,
decreased significantly in the test group as compared to the
control group, confirming the dilution effect of increased
water intake (Table 2). Consistently, urine osmolality and
urine specific gravity also significantly decreased (Table 3).
These results indicate good compliance of water intake by
the test group and no change in water intake by the control
group.
3.4. Smoking Habits. The mean number of cigarettes con-
sumed/day (±SD) remained stable between baseline and
study end in both the test group (from 20.5±5.4 to 20.7±4.8)
and the control group (20.3 ± 4.0 to 21.3 ± 3.8), with no
difference in the change (0.2 ± 3.6 for the test group versus
0.8 ± 3.2 for the control group; 𝑝 = 0.121). In addition,
mean Fagerstro¨m scores (±SD) were similar and changed
little between baseline and study end in the test group (from
7.2 ± 1.4 to 7.4 ± 1.3) and in the control group (from 7.2 ± 1.3
to 7.4 ± 1.1).
3.5. Nutrient Intake. Changes in nutrient consumption (total
energy and grams carbohydrate, protein, fat, fiber, and
sodium) between baseline and study end were not signifi-
cantly different between the test and control groups (data not
shown).
3.6. Urinary Mutagenicity. Mutagenic activity of the urine
in vitro was decreased significantly in the test group from
206 revertants/mL to 101 revertants/mL by the end of the
study. This indicates a mean net loss of ±SD of 114.19 ±
119.49 revertants/mL (53.6% decrease) in the test group,
whereas in the control group, mutagenic activity changed lit-
tle (140.9 revertants/mL at initial assay and 153 revertants/mL
at completion). The decrease in mutagenic activity was
significantly greater in the test group (𝑝 < 0.001).
These data taken together indicate that although the
smoking habits and excretion of total mutagens in the urine
did not change in the study population, the increased urine
output induced a concomitant dilution of mutagens excreted
in urine. In addition, since urine output increased in the
test group, the urinary frequency and therefore the time
urothelial cells were exposed to mutagens decreased. Thus,
the bladder cells were exposed to significantly more dilute
urine for a shorter amount of time between voids.
3.7. DNA Adduct Levels in Exfoliated Urothelial Cells. In
subjects completing the study according to protocol, mean 4-
ABP-DNA and BPDE-DNA adduct levels were between 0.4
and 0.8 per 108 nonadducted nucleotides (Table 4).The levels
of these adducts decreased slightly (<0.2 per 108 nonadducted
nucleotides) between baseline and study end but with no
significant differences between groups. Adduct levels at both
baseline and study end were highly variable, as indicated by
large SDs.
Results were similar when assessed in the full set of all
randomized subjects (data not shown). No correlation was
found between urinary mutagenicity and 4-ABP-DNA or
BPDE-DNA adducts formation (data not shown).
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Table 2: Blood chemistry changes after intervention in test group versus control group.
Measure Test Control All 𝑃 value
𝑛 (mean ± SD) 𝑛 (mean ± SD) 𝑛 (mean ± SD)
Osmolality (mOsm/kg)
Baseline 32 (300.3 ± 4.7) 32 (298.8 ± 6.5) 64 (299.5 ± 5.6)
Study end 31 (297.0 ± 2.8) 31 (300.1 ± 4.1) 62 (298.5 ± 3.8)
Absolute raw change 31 (−3.4 ± 5.4) 31 (1.3 ± 7.7) 62 (−1.0 ± 7.0)
Adjusted mean change (SE) −2.6 ± 0.6 0.5 ± 0.6 0.001
Values are shown for all subjects randomized and for whom data were available. SD, standard deviation; SE, standard error of the mean.
𝑃 value determined by analysis of covariance, adjusted for baseline values (parameter and cigarettes consumption).
Table 3: Urinary chemistry changes after intervention in test group versus control group.
Measure Test Control All 𝑃 value
𝑛 (mean ± SD) 𝑛 (mean ± SD) 𝑛 (mean ± SD)
Excretion
Osmolality (mOsm/kg)
Baseline 32 (910.7 ± 105.3) 32 (908.2 ± 113.7) 64 (909.5 ± 108.7)
Study end 31 (410.4 ± 130.6) 31 (827.1 ± 224.2) 62 (618.7 ± 277.9)
Absolute raw change 31 (−502.1 ± 164.3) 31 (−84.8 ± 215.4) 62 (−293.5 ± 283.5)
Adjusted mean change (SE) −501.7 ± 32.5 −85.2 ± 32.5 <0.001
Urine specific gravity (g/mL)
Baseline 32 (1.0246 ± 0.0033) 32 (1.0252 ± 0.0034) 64 (1.0249 ± 0.0033)
Study end 31 (1.0115 ± 0.0037) 31 (1.0231 ± 0.0059) 62 (1.0173 ± 0.0076)
Absolute raw change 31 (−0.0131 ± 0.0049) 31 (−0.0022 ± 0.0063) 62 (−0.0077 ± 0.0079)
Adjusted mean change (SE) −0.013 ± 0.0009 −0.0019 ± 0.0009 <0.001
Values are shown for all subjects randomized and for whom data were available. SD, standard deviation; SE, standard error of the mean.
𝑃 value determined by analysis of covariance, adjusted for baseline values (parameter and cigarettes consumption).
Table 4: Adducts and mutagenicity.
Measure Test Control All 𝑃 value
𝑛 (mean ± sd) 𝑛 (mean ± sd) 𝑛 (mean ± sd)
4-ABP-DNA log (adducts/108 DNA unadducted nucleotides)
Baseline 32 (0.545 ± 0.762) 32 (0.608 ± 0.834) 64 (0.577 ± 0.793)
Study end 31 (0.502 ± 0.705) 31 (0.528 ± 0.696) 62 (0.515 ± 0.695)
Absolute raw change 31 (−0.056 ± 1.087) 31 (−0.054 ± 0.930) 62 (−0.055 ± 1.003)
Adjusted mean change (SE) −0.068 ± 0.127 −0.042 ± 0.127 0.889b
BPDE-DNA log (adducts/108 DNA unadducted nucleotides)
Baseline 32 (0.551 ± 0.806) 32 (0.396 ± 0.948) 64 (0.473 ± 0.876)
Study end 31 (0.378 ± 0.781) 31 (0.414 ± 0.825) 62 (0.396 ± 0.797)
Absolute raw change 31 (−0.222 ± 1.017) 31 (0.037 ± 1.097) 62 (−0.093 ± 1.057)
Adjusted mean change (SE) −0.131 (0.144) −0.054 (0.144) 0.708b
Mutagenic activity (revertants/mL)
Baseline 32 (205.80 ± 138.82) 31 (140.89 ± 90.60) 63 (173.86 ± 121.15)
Study end 30 (100.51 ± 53.67) 29 (152.97 ± 104.95) 59 (126.29 ± 86.35)
Absolute raw change 30 (−108.53 ± 121.45) 28 (1.11 ± 61.46) 58 (−55.60 ± 111.12)
Median [Q1; Q3] for raw change −80.70 [−184.00; −24.10] 2.40 [−27.75; 32.70] <0.001a
Values are shown for all subjects randomized and for whom data were available. SD, standard deviation; SE, standard error of the mean.
a
𝑃 value determined by Wilcoxon Rank-Sum test.
b
𝑃 value determined by analysis of covariance, adjusted for baseline values (parameter and cigarettes consumption).
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4. Discussion
Several hypotheses have been proposed for the mechanism
by which fluid intakemay decrease the risk of bladder cancer,
although the “urogenous contact hypothesis” is the most
commonly considered. Braver et al. observed that the inci-
dence of bladder cancer differs in urban and rural working
populations and that this difference correlates with urine
concentration and less frequent micturition [17]. Accord-
ingly, prolonged contact of carcinogens in the urine with the
urothelium was proposed to increase bladder cancer risk.
According to this model, higher fluid intake, which should
result in a higher volume and frequency of urination, would
reduce the contact time and limit the effects of carcino-
gens on bladder tissue [12]. Mechanistic studies in animals
support this hypothesis, but data from humans are lacking
[14].
We designed a controlled proof-of-concept trial to assess
the effect of increasedwater intake onDNAadduct formation
and mutagenicity in the urothelial cells from smokers. For
this study, we recruited 64 smokers with low fluid intake
(<1 L/day). Recruiting subjects with such a low total fluid
intake was easily achieved, in agreement with Vergne et al.
who reported that 21% of the French adult population has a
fluid intake lower than 1 L/day [18].
This study did not find a difference in the levels of the
tested adducts in the urine of subjects who had an increase
of water intake compared to the low water intake control
group. We suspect that the lack of a significant effect on
DNA adducts was principally due to high interindividual
variability in DNA adduct levels, assay variability and the
relatively small sample size, and the relatively short treatment
period, which may not have allowed full expression of the
differences to become manifest. In fact, previous studies
have noted high interindividual differences in adduct levels.
For example, DNA binding by 4-ABP is estimated to vary
between individuals by as much as one millionfold between
the most and least susceptible individuals [13]. The ability
to detect differences in DNA adducts could also have been
reduced by insufficient turnover of the urothelium during the
50 days of this study; the lifetime of the urothelium has been
estimated to be 50 to 200 days [19], and a turnover rate at
the high end of this range would have reduced the ability to
detect differences. Alternatively, a larger sample size will be
necessary to detect significant differences.
Urinary mutagenicity was also assessed in our study as a
complementary test to evaluate themutagenic potential of the
collected urine. Mutagenic activity was significantly lower in
the test group than in the control group. This result seems to
be in line with the urogenous contact theory [18]: abundant
water intake, and consequently diluted urine, would decrease
the time of contact between the carcinogens in urine and
DNA and lead to a decrease in the number of mutations.
However, the mutagenicity test employed prokaryotic cells,
which might not necessarily be predictive of mutagenicity in
mammalian cells.
DNA adducts in the exfoliated urothelium and urinary
mutagenicity integrate exposure to mutagens over very
different amounts of time. The concentration of urinary
mutagens is essentially ameasure of short-term exposure and
is expected to decrease rapidly if the amount of mutagen
remains the same but the urine volume increased. In contrast,
DNA adduct levels in exfoliated urothelial cells integrate
exposure over the lifespan of the urothelium, which has been
variously estimated to be 50 to 200 days [20]. Therefore,
even a 50% reduction in exposure (as indicated by urine
mutagenicity) would be only slowly translated into reduced
levels of DNA adducts as the urothelial cells are exfoliated.
Reduction in adduct levels would be slower if the lifespan
of the urothelium was greater than 50 days. In support
of this hypothesis, Henn et al. reported that the levels of
urinary metabolites are only slightly and nonsignificantly
lower in thewives of nonsmokers than in thewives of smokers
but that DNA adduct levels were significantly lower in the
wives of nonsmokers, suggesting that chronic higher expo-
sure to mutagens in secondhand smoke eventually caused
a significant increase in carcinogenic DNA adduct levels
[20].
To date, most investigations on the effects of water
intake on bladder cancer have been retrospective analyses of
observational data [9–13]. These are susceptible to bias, and
we wanted to use a strong methodological approach, so we
designed a randomized, controlled, parallel-group study in
which the eligibility criteria were narrowly defined and in
which natural mineral water with a low mineral content was
used. This reduced the influence of potential confounders,
such as concomitant illnesses, tap water contaminants, and
high mineral content. We also confirmed that compliance
with the study procedures was excellent and that dietary
and smoking habits did not significantly differ between the
groups.
5. Conclusion
As far as we know, this is the first time that the hypothesis that
increased water intake significantly decreases urinary muta-
genicity has been proven. Consequently, increasing water
intake might be a low cost and safe approach to eventually
reduce risk of mutagenesis in exposed populations. However,
this hypothesis needs to be confirmed with long term and
statistically well-powered clinical studies. Our investigation
yielded important data that will be useful for the design of
these future studies.
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